Lundbeck (HLUYY) Cut to “Hold” at Zacks Investment Research

Lundbeck (OTCMKTS:HLUYY) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Shares of OTCMKTS HLUYY opened at $57.01 on Wednesday. The stock has a market cap of $11,553.24, a price-to-earnings ratio of 34.52, a price-to-earnings-growth ratio of 3.63 and a beta of -0.01. The company has a quick ratio of 1.13, a current ratio of 1.36 and a debt-to-equity ratio of 0.07. Lundbeck has a 1 year low of $46.05 and a 1 year high of $66.67.

COPYRIGHT VIOLATION WARNING: “Lundbeck (HLUYY) Cut to “Hold” at Zacks Investment Research” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at

About Lundbeck

H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Denmark and internationally. Its products include Abilify Maintena, Brintellix/Trintellix, Cipralex/Lexapro, Northera, Onfi, Rexulti, Sabril, and Xenazine.

Get a free copy of the Zacks research report on Lundbeck (HLUYY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Lundbeck Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lundbeck and related companies with's FREE daily email newsletter.

Leave a Reply